Discontinued — last reported Q1 '22
Non-Current Assets
Equity securities
Pfizer Equity securities increased by 41.7% to $2.39B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 68.3%, from $1.42B to $2.39B. Over 4 years (FY 2020 to FY 2024), Equity securities shows an upward trend with a 92.9% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryCapital Allocation
SignalHigher is better
VolatilityVolatile
First reportedQ1 2019
Last reportedQ1 2022
How to read this metric
An increase reflects positive market performance of the underlying investments or additional capital deployment into equities.
Detailed definition
This represents the fair market value of the company's investment portfolio consisting of equity securities in other ent...
Peer comparison
Standard for companies with large corporate venture arms or significant treasury investment portfolios.
Metric ID:
ins_equity_securitiesHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.28B | $2.37B | $5.37B | $2.76B | $4.37B | $12.15B | $1.59B | $1.17B | $17.64B | $13.19B | $5.12B | $2.48B | $975.00M | $1.42B | $7.85B | $1.26B | $1.69B | $2.39B |
| QoQ Change | — | +3.6% | +126.7% | -48.6% | +58.5% | +177.9% | -86.9% | -26.6% | >999% | -25.2% | -61.2% | -51.5% | -60.7% | +45.6% | +452.7% | -84.0% | +34.4% | +41.7% |
| YoY Change | — | — | — | — | +91.5% | +413.5% | -70.4% | -57.8% | +303.4% | +8.5% | +222.7% | +113.1% | -94.5% | -89.2% | +53.2% | -49.5% | +73.0% | +68.3% |
Range$975.00M – $17.64B
CAGR+1.1%
Avg YoY Growth+70.4%
Median YoY Growth+60.7%
Current Streak2 quarters growth
Equity securities at Other Companies
Frequently Asked Questions
- What is Pfizer's equity securities?
- Pfizer (PFE) reported equity securities of $2.39B in Q3 2025.
- How has Pfizer's equity securities changed year-over-year?
- Pfizer's equity securities increased by 68.3% year-over-year, from $1.42B to $2.39B.
- What is the long-term trend for Pfizer's equity securities?
- Over 4 years (2020 to 2024), Pfizer's equity securities has grown at a 92.9% compound annual growth rate (CAGR), from $567.00M to $7.85B.
- What does equity securities mean?
- The current market value of the company's stock investments in other businesses.